GO
Loading...

Amgen Inc

More

  • Final Glance: Biotechnology companies Friday, 17 Apr 2015 | 6:03 PM ET

    Amgen Inc. fell $3.29 or 2.0 percent, to $163.58. Biogen Idec fell $9.21 or 2.1 percent, to $419.44. Celgene Corp. fell $2.89 or 2.5 percent, to $113.47.

  • Midday Glance: Biotechnology companies Friday, 17 Apr 2015 | 1:17 PM ET

    Amgen Inc. fell $4.27 or 2.6 percent, to $162.60. Biogen Idec fell $8.80 or 2.1 percent, to $419.85. Celgene Corp. fell $2.47 or 2.1 percent, to $113.89.

  • Early Glance: Biotechnology companies Friday, 17 Apr 2015 | 10:57 AM ET

    Amgen Inc. fell $3.39 or 2.0 percent, to $163.48. Biogen Idec fell $7.44 or 1.7 percent, to $421.21. Celgene Corp. fell $2.02 or 1.7 percent, to $114.34.

  • Final Glance: Biotechnology companies Thursday, 16 Apr 2015 | 6:03 PM ET

    Amgen Inc. rose $1.40 or. 8 percent, to $166.87. Biogen Idec fell $2.31 or. 5 percent, to $428.65. Celgene Corp. fell $1.87 or 1.6 percent, to $116.36.

  • Midday Glance: Biotechnology companies Thursday, 16 Apr 2015 | 1:28 PM ET

    Amgen Inc. rose $1.15 or. 7 percent, to $166.62. Biogen Idec fell$. 01 or percent, to $430.95. Celgene Corp. fell $1.65 or 1.4 percent, to $116.58.

  • Final Glance: Biotechnology companies Wednesday, 15 Apr 2015 | 5:57 PM ET

    Amgen Inc. rose $2.90 or 1.8 percent, to $165.47. Biogen Idec rose $7.39 or 1.7 percent, to $430.96. Celgene Corp. rose $2.45 or 2.1 percent, to $118.23.

  • April 15- U.S. health regulators on Wednesday approved Amgen Inc's Corlanor to treat patients with chronic heart failure, giving the world's largest biotechnology company its first cardiovascular product. RBC Capital Markets analyst Michael Yee said that long term Corlanor could become a $500 million a year drug for Amgen. Amgen shares rose 1.3 percent in...

  • FDA approves new type of heart failure drug from Amgen Wednesday, 15 Apr 2015 | 4:53 PM ET

    TRENTON, N.J.— Patients with chronic heart failure, a disabling, deadly disease that worsens as the heart gradually pumps less efficiently, are getting a much-needed new option with U.S. approval Wednesday of a novel drug from Amgen Inc.. Meanwhile, the Food and Drug Administration is reviewing another heart failure pill, from Novartis AG, and could approve it this...

  • Midday Glance: Biotechnology companies Wednesday, 15 Apr 2015 | 2:34 PM ET

    Amgen Inc. rose $1.99 or 1.2 percent, to $164.56. Biogen Idec rose $6.10 or 1.4 percent, to $429.67. Celgene Corp. rose $1.68 or 1.5 percent, to $117.46.

  • Final Glance: Biotechnology companies Tuesday, 14 Apr 2015 | 5:58 PM ET

    Amgen Inc. rose$. 08 or percent, to $162.57. Biogen Idec rose$. 21 or percent, to $423.57. Celgene Corp. fell$. 66 or. 6 percent, to $115.78.

  • Midday Glance: Biotechnology companies Tuesday, 14 Apr 2015 | 1:34 PM ET

    Amgen Inc. fell$. 70 or. 4 percent, to $161.79. Biogen Idec fell $3.32 or. 8 percent, to $420.04. Celgene Corp. fell $1.10 or. 9 percent, to $115.34.

  • Early Glance: Biotechnology companies Tuesday, 14 Apr 2015 | 10:42 AM ET

    Amgen Inc. fell $1.12 or. 7 percent, to $161.37. Biogen Idec fell $3.22 or. 8 percent, to $420.14. Celgene Corp. fell$. 43 or. 4 percent, to $116.01.

  • Final Glance: Biotechnology companies Monday, 13 Apr 2015 | 6:00 PM ET

    Amgen Inc. fell$. 89 or. 5 percent, to $162.49. Biogen Idec fell $2.29 or. 5 percent, to $423.36. Celgene Corp. fell$. 63 or. 5 percent, to $116.44.

  • Midday Glance: Biotechnology companies Monday, 13 Apr 2015 | 1:19 PM ET

    Amgen Inc. fell$. 05 or percent, to $163.33. Biogen Idec rose $1.39 or. 3 percent, to $427.04. Celgene Corp. rose$. 52 or. 4 percent, to $117.59.

  • Early Glance: Biotechnology companies Monday, 13 Apr 2015 | 10:27 AM ET

    Amgen Inc. rose$. 71 or. 4 percent, to $164.09. Biogen Idec rose $4.25 or 1.0 percent, to $429.89. Celgene Corp. rose$. 35 or. 3 percent, to $117.42.

  • Final Glance: Biotechnology companies Friday, 10 Apr 2015 | 6:05 PM ET

    Amgen Inc. rose $1.89 or 1.2 percent, to $163.38. Biogen Idec fell$. 98 or. 2 percent, to $425.65. Celgene Corp. rose $1.49 or 1.3 percent, to $117.07.

  • Midday Glance: Biotechnology companies Friday, 10 Apr 2015 | 1:25 PM ET

    Amgen Inc. rose $1.61 or 1.0 percent, to $163.10. Biogen Idec fell $1.19 or. 3 percent, to $425.44. Celgene Corp. rose $1.27 or 1.1 percent, to $116.85.

  • Early Glance: Biotechnology companies Friday, 10 Apr 2015 | 10:28 AM ET

    Amgen Inc. fell$. 14 or. 1 percent, to $161.35. Biogen Idec fell $1.97 or. 5 percent, to $424.66. Celgene Corp. rose$. 76 or. 7 percent, to $116.34.

  • Final Glance: Biotechnology companies Thursday, 9 Apr 2015 | 6:14 PM ET

    Amgen Inc. rose $1.16 or. 7 percent, to $161.49. Biogen Idec rose $1.27 or. 3 percent, to $426.63. Celgene Corp. rose$. 43 or. 4 percent, to $115.58.

  • Midday Glance: Biotechnology companies Thursday, 9 Apr 2015 | 1:41 PM ET

    Amgen Inc. rose$. 85 or. 5 percent, to $161.18. Biogen Idec fell $1.15 or. 3 percent, to $424.21. Celgene Corp. fell$. 16 or. 1 percent, to $114.99.